XML 45 R16.htm IDEA: XBRL DOCUMENT
v2.4.0.6

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION | 12 Months Ended
--- | ---
Dec. 31, 2011
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION | NOTE 9 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION: Balance sheets:
|  | December 31, |
|  | 2010 |  |  | 2011 |
a. Accounts receivable - other: |  |  |  |  |  |  |  |
Deferred costs* |  |  |  |  |  | $ | 1,558 |
Institutions |  | $ | 634 |  |  |  | 375 |
State of Israel (see Note 6a ) |  |  | 878 |  |  |  | 1,296 |
Restricted deposit |  |  | 226 |  |  |  | 208 |
Prepaid expenses |  |  | 354 |  |  |  | 235 |
Sundry |  |  | 139 |  |  |  | 165 |
|  | $ | 2,231 |  |  | $ | 3,837 |
* Manufacturing costs of inventory, paid by Pfizer, but not delivered. |  |  |  |  |  |  |  |
b. Accounts payable and accruals – other: |  |  |  |  |  |  |  |
Payroll and related expenses |  | $ | 1,199 |  |  | $ | 1,108 |
Provision for vacation and recreation pay |  |  | 1,235 |  |  |  | 1,221 |
Accrued expenses |  |  | 2,030 |  |  |  | 2,327 |
Royalties payable |  |  | 884 |  |  |  | 89 |
Liability in connection with collaboration operation- current portion |  |  |  |  |  |  | 1,322 |
Property and equipment supplier |  |  | 2,720 |  |  |  | 1,473 |
|  | $ | 8,068 |  |  | $ | 7,540 |
Statement of operations:
|  | Year ended December 31, |
|  | 2009 |  |  | 2010 |  |  | 2011 |
c. Revenues: |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenues from the license and supply agreement with Pfizer |  | $ | 388 |  |  | $ | 4,563 |  |  | $ | 4,563 |
Revenues from selling products to Pfizer |  |  |  |  |  |  | 2,079 |  |  |  | 3,823 |
|  | $ | 388 |  |  | $ | 6,642 |  |  | $ | 8,386 |
d. Cost of Revenues: |  |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  | $ | 807 |  |  | $ | 985 |
Write down of inventories |  |  |  |  |  |  | 2,692 |  |  |  | 363 |
Royalties expenses |  | $ | 3,575 |  |  |  | 884 |  |  |  | 177 |
|  | $ | 3,575 |  |  | $ | 4,383 |  |  | $ | 1,525 |
e. Research and development expenses - net: |  |  |  |  |  |  |  |  |  |  |  |
Payroll and related expenses |  | $ | 10,479 |  |  | $ | 13,176 |  |  | $ | 14,042 |
Subcontractors and consultants |  |  | 7,469 |  |  |  | 11,550 |  |  |  | 11,314 |
Materials and consumables |  |  | 3,852 |  |  |  | 4,947 |  |  |  | 3,425 |
Rent, insurance and maintenance |  |  | 2,238 |  |  |  | 3,457 |  |  |  | 4,113 |
Patent registration and licensing |  |  | 387 |  |  |  | 571 |  |  |  | 449 |
Depreciation and write down |  |  | 1,799 |  |  |  | 2,456 |  |  |  | 3,057 |
Other |  |  | 1,166 |  |  |  | 1,534 |  |  |  | 1,418 |
|  |  | 27,390 |  |  |  | 37,691 |  |  |  | 37,818 |
Less - grants and reimbursements: |  |  |  |  |  |  |  |  |  |  |  |
Development costs reimbursements from Pfizer |  |  |  |  |  |  | 3,922 |  |  |  | 3,430 |
Grants (see Note 6a) |  |  | 5,752 |  |  |  | 3,818 |  |  |  | 3,345 |
|  | $ | 21,638 |  |  | $ | 29,951 |  |  | $ | 31,043 |
f. General and administrative expense: |  |  |  |  |  |  |  |  |  |  |  |
Payroll and related expenses |  | $ | 2,804 |  |  | $ | 2,415 |  |  | $ | 2,481 |
Management and consulting fees |  |  | 681 |  |  |  | 221 |  |  |  | 215 |
Rent, insurance and maintenance |  |  | 347 |  |  |  | 463 |  |  |  | 498 |
Professional fees |  |  | 2,274 |  |  |  | 2,274 |  |  |  | 2,326 |
Travel |  |  | 251 |  |  |  | 308 |  |  |  | 229 |
Depreciation |  |  | 191 |  |  |  | 309 |  |  |  | 363 |
Other |  |  | 596 |  |  |  | 886 |  |  |  | 819 |
|  | $ | 7,144 |  |  | $ | 6,876 |  |  | $ | 6,931

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration